Skip to main content
Top
Published in: BMC Palliative Care 1/2020

Open Access 01-12-2020 | Cancer Therapy | Research article

Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis

Authors: Ulrich Kaiser, Ursula Vehling-Kaiser, Fabian Kück, Nicolae-Catalin Mechie, Ana Hoffmann, Florian Kaiser

Published in: BMC Palliative Care | Issue 1/2020

Login to get access

Abstract

Background

There is controversy regarding the practical implementation of symptom-focused oncological cancer therapies to hospice residents. In this study, we aim to analyse the use and indication of supportive-oncological cancer therapies in hospices.

Methods

We conducted a retrospective survey of all residents of two hospice centres in the government district of Lower Bavaria, Germany. Hospice 1 (H1) was a member of an oncological–palliative medical network, and hospice 2 (H2) was independently organized. The evaluation period was the first 40 months after the opening of the respective hospice care centre. Demographical and epidemiological data as well as indications and type of supportive-oncological cancer therapies were recorded. A descriptive analysis and statistical tests were performed.

Results

Of the 706 residents, 645 had an underlying malignant disease. The average age was 72 years and the mean residence time was 28 days. The most frequent cancer types were gastrointestinal cancers, gynaecological cancers and bronchial carcinomas. Overall 39 residents (33 in H1 and 6 in H2, p < 0.01) received symptom-focused oncological cancer therapy. The average age of these residents was 68 years, and the mean residence time was 55 days. The most common therapeutic indications were dyspnoea and pain. The most common symptom-focused oncological cancer therapies were bisphosphonates, transfusions (erythrocyte- and platelet- concentrates), radiotherapy and anti-proliferative drugs (chemotherapy, anti-hormonal- and targeted- therapies). Patients with therapy lived significantly longer than patients without therapy (p < 0.01).

Conclusions

Symptom-focused oncological cancer therapies can be implemented in hospices; however, their implementation seems to require certain structural and organizational prerequisites as well as careful patient selection. As a palliative medical approach, the focus is to ameliorate the symptoms and not prolong life. Symptom-focused oncology treatment could be a further and important part for the therapy of hospice patients in the future.
Literature
1.
go back to reference Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–42.CrossRef Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–42.CrossRef
2.
go back to reference Farbicka P, Nowicki A. Palliative care in patients with lung cancer. Contemp Oncol (Pozn). 2013;17:238–45. Farbicka P, Nowicki A. Palliative care in patients with lung cancer. Contemp Oncol (Pozn). 2013;17:238–45.
3.
go back to reference Hui D, Bruera E. Integrating palliative care into the trajectory of cancer care. Nat Rev Clin Oncol. 2016;13:159–71.CrossRef Hui D, Bruera E. Integrating palliative care into the trajectory of cancer care. Nat Rev Clin Oncol. 2016;13:159–71.CrossRef
4.
go back to reference Parikh R, Kirch R, Smith T, et al. Early specialty palliative care — translating data in oncology into practice. N Engl J Med. 2013;369:2347–51.CrossRef Parikh R, Kirch R, Smith T, et al. Early specialty palliative care — translating data in oncology into practice. N Engl J Med. 2013;369:2347–51.CrossRef
5.
go back to reference Howie L, Peppercorn J. Early palliative care in cancer treatment: rationale, evidence and clinical implications. Ther Adv Med Oncol. 2013;5:318–23.CrossRef Howie L, Peppercorn J. Early palliative care in cancer treatment: rationale, evidence and clinical implications. Ther Adv Med Oncol. 2013;5:318–23.CrossRef
6.
go back to reference Park K, Lee C, Tseng Y, et al. Palliative radiation therapy in the last 30 days of life: a systematic review. Radiother Oncol. 2017;125:193–9.CrossRef Park K, Lee C, Tseng Y, et al. Palliative radiation therapy in the last 30 days of life: a systematic review. Radiother Oncol. 2017;125:193–9.CrossRef
7.
go back to reference Barthelemy N, Jansen N, Gennigens C, et al. Does radiotherapy have a role in end-of-life care? Rev Med Liege. 2012;67:128–32.PubMed Barthelemy N, Jansen N, Gennigens C, et al. Does radiotherapy have a role in end-of-life care? Rev Med Liege. 2012;67:128–32.PubMed
8.
go back to reference van Oorschot B, Schuler M, Simon A, et al. Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis. Strahlenther Onkol. 2011;187:461–6.CrossRef van Oorschot B, Schuler M, Simon A, et al. Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis. Strahlenther Onkol. 2011;187:461–6.CrossRef
9.
go back to reference LeBlanc T, Egan P, Olszewski A. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018;132:717–26.CrossRef LeBlanc T, Egan P, Olszewski A. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018;132:717–26.CrossRef
10.
go back to reference Orme J, Still D, Day R, et al. The experiences of patients undergoing blood transfusion in a day hospice. Int J Palliat Nurs. 2013;19:171–6.CrossRef Orme J, Still D, Day R, et al. The experiences of patients undergoing blood transfusion in a day hospice. Int J Palliat Nurs. 2013;19:171–6.CrossRef
11.
go back to reference Mitra R, Jones S. Adjuvant analgesics in cancer pain: a review. Am J Hosp Palliat Care. 2012;29:70–9.CrossRef Mitra R, Jones S. Adjuvant analgesics in cancer pain: a review. Am J Hosp Palliat Care. 2012;29:70–9.CrossRef
12.
go back to reference Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29:166–91.CrossRef Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29:166–91.CrossRef
13.
go back to reference Schonwetter R, Roscoe L, Nwosu M, et al. Quality of life and symptom control in hospice patients with cancer receiving chemotherapy. J Palliat Med. 2006;9:638–45.CrossRef Schonwetter R, Roscoe L, Nwosu M, et al. Quality of life and symptom control in hospice patients with cancer receiving chemotherapy. J Palliat Med. 2006;9:638–45.CrossRef
14.
go back to reference Haverhals L, Manheim C, Mor V, et al. The experience of providing hospice care concurrent with cancer treatment in the VA. Support Care Cancer. 2019;27:1263–70.CrossRef Haverhals L, Manheim C, Mor V, et al. The experience of providing hospice care concurrent with cancer treatment in the VA. Support Care Cancer. 2019;27:1263–70.CrossRef
15.
go back to reference Mor V, Joyce N, Coté D, et al. The rise of concurrent care for veterans with advanced cancer at the end of life. Cancer. 2016;122:782–90.CrossRef Mor V, Joyce N, Coté D, et al. The rise of concurrent care for veterans with advanced cancer at the end of life. Cancer. 2016;122:782–90.CrossRef
16.
go back to reference Mor V, Wagner T, Levy C, et al. Association of Expanded VA hospice care with aggressive care and cost for veterans with advanced lung Cancer. JAMA Oncol. 2019;5:810–6.CrossRef Mor V, Wagner T, Levy C, et al. Association of Expanded VA hospice care with aggressive care and cost for veterans with advanced lung Cancer. JAMA Oncol. 2019;5:810–6.CrossRef
17.
go back to reference Loriot Y, Miller K, Sternberg C, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16:509–21.CrossRef Loriot Y, Miller K, Sternberg C, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16:509–21.CrossRef
18.
go back to reference Tombal B, Saad F, Penson D, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:556–69.CrossRef Tombal B, Saad F, Penson D, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:556–69.CrossRef
20.
go back to reference Prigerson H, Bao Y, Shah M, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778–84.CrossRef Prigerson H, Bao Y, Shah M, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778–84.CrossRef
21.
go back to reference Zhang B, Nilsson M, Prigerson H. Factors important to patients’ quality of life at the end of life. Arch Intern Med. 2012;172:1133–42.PubMedPubMedCentral Zhang B, Nilsson M, Prigerson H. Factors important to patients’ quality of life at the end of life. Arch Intern Med. 2012;172:1133–42.PubMedPubMedCentral
22.
go back to reference Wu C, Hsu T, Chang C, et al. Palliative chemotherapy affects aggressiveness of end-of-life care. Oncologist. 2016;21:771–7.CrossRef Wu C, Hsu T, Chang C, et al. Palliative chemotherapy affects aggressiveness of end-of-life care. Oncologist. 2016;21:771–7.CrossRef
23.
24.
go back to reference Casarett D, Fishman J, Lu H, et al. The terrible choice: re-evaluating hospice eligibility criteria for cancer. J Clin Oncol. 2009;27:953–9.CrossRef Casarett D, Fishman J, Lu H, et al. The terrible choice: re-evaluating hospice eligibility criteria for cancer. J Clin Oncol. 2009;27:953–9.CrossRef
25.
go back to reference Casarett D, Van Ness P, O'Leary J, et al. Are patient preferences for life-sustaining treatment really a barrier to hospice enrollment for older adults with serious illness? J Am Geriatr Soc. 2006;54:472–8.CrossRef Casarett D, Van Ness P, O'Leary J, et al. Are patient preferences for life-sustaining treatment really a barrier to hospice enrollment for older adults with serious illness? J Am Geriatr Soc. 2006;54:472–8.CrossRef
26.
go back to reference Casarett D, Fishman J, O'Dwyer P, et al. How should we design supportive cancer care? The patient's perspective. J Clin Oncol. 2008;26:1296–301.CrossRef Casarett D, Fishman J, O'Dwyer P, et al. How should we design supportive cancer care? The patient's perspective. J Clin Oncol. 2008;26:1296–301.CrossRef
27.
go back to reference Balboni T. Hospice and anticancer therapy-shifting from an either/or to a both/and treatment model. JAMA Oncol. 2019;5:786–7.CrossRef Balboni T. Hospice and anticancer therapy-shifting from an either/or to a both/and treatment model. JAMA Oncol. 2019;5:786–7.CrossRef
34.
go back to reference Oechsle K. Palliative Care in Patients with hematological malignancies. Oncol Res Treat. 2019;42:25–30.CrossRef Oechsle K. Palliative Care in Patients with hematological malignancies. Oncol Res Treat. 2019;42:25–30.CrossRef
35.
go back to reference Kaiser F, Rudloff L, Vehling-Kaiser U, et al. Palliative home care for patients with advanced haematological malignancies-a multicenter survey. Ann Hematol. 2017;96:1557–62.CrossRef Kaiser F, Rudloff L, Vehling-Kaiser U, et al. Palliative home care for patients with advanced haematological malignancies-a multicenter survey. Ann Hematol. 2017;96:1557–62.CrossRef
36.
go back to reference Schneider W, Eichner E, Thoms U, et al. Specialised out-patient palliative care (SAPV) in Bavaria: efficiency, structural and process-related effects and rural care. Gesundheitswesen. 2015;77:219–24.CrossRef Schneider W, Eichner E, Thoms U, et al. Specialised out-patient palliative care (SAPV) in Bavaria: efficiency, structural and process-related effects and rural care. Gesundheitswesen. 2015;77:219–24.CrossRef
38.
go back to reference Mercadante S, Ferrera P, Villari P, et al. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med. 2009;12:60–3.CrossRef Mercadante S, Ferrera P, Villari P, et al. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med. 2009;12:60–3.CrossRef
39.
go back to reference Meystre C, Burley N, Ahmedzai S. What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses. BMJ. 1997;1997:1202–3.CrossRef Meystre C, Burley N, Ahmedzai S. What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses. BMJ. 1997;1997:1202–3.CrossRef
40.
go back to reference Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, et al. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017;31:5–25.CrossRef Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, et al. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017;31:5–25.CrossRef
41.
go back to reference Tannock I, Osoba D, Stockler M, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.CrossRef Tannock I, Osoba D, Stockler M, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.CrossRef
42.
go back to reference Lahoud M, Kourie H, Antoun J, et al. Road map for pain management in pancreatic cancer: a review. World J Gastrointest Oncol. 2016;8:599–606.CrossRef Lahoud M, Kourie H, Antoun J, et al. Road map for pain management in pancreatic cancer: a review. World J Gastrointest Oncol. 2016;8:599–606.CrossRef
Metadata
Title
Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis
Authors
Ulrich Kaiser
Ursula Vehling-Kaiser
Fabian Kück
Nicolae-Catalin Mechie
Ana Hoffmann
Florian Kaiser
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Palliative Care / Issue 1/2020
Electronic ISSN: 1472-684X
DOI
https://doi.org/10.1186/s12904-020-00648-4

Other articles of this Issue 1/2020

BMC Palliative Care 1/2020 Go to the issue